<DOC>
	<DOCNO>NCT02697474</DOCNO>
	<brief_summary>The aim study assess persistence anti-Hep B antibody 9 10 year age last priming dose subject complete study A3L12 ( NCT00401531 ) , also evaluate immune response hepatitis B one month vaccination ( challenge vaccination ) stand alone monovalent hepatitis B vaccine . Primary objective : - To describe persistence anti-hepatitis B antibody 9 10 year age last priming dose subject receive hepatitis B vaccine birth hexavalent vaccine 2 , 4 6 month age accord vaccine receive A3L12 study ( Hexaxim® [ Group 1 ] Infanrix® hexa [ Group 2 ] ) - To evaluate immune response hepatitis B one month vaccination stand alone monovalent hepatitis B vaccine ( challenge vaccination ) . Secondary objective : - To describe serious adverse event ( SAEs ) report throughout trial administration hepatitis B vaccine .</brief_summary>
	<brief_title>Anti-Hep B Antibodies Age 9 10 Years After Hep B Vaccine Birth DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine .</brief_title>
	<detailed_description>Subjects age 9 10 year receive 3 injection Hexaxim® Infanrix® hexa complete A3L12 study invite participate study . They receive one dose Euvax-B® vaccine Day 0 .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Informed consent form sign subject 's parent/legally acceptable representative Assent form sign subject Subject parent ( ) /legally acceptable representative able attend schedule visit comply trial procedure Receipt primary vaccination 3 dos either Hexaxim® Infanrix® hexa age 2 , 4 , 6 month A3L12 study , hepatitis B vaccine birth . Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede inclusion trial Incomplete primary immunization A3L12 study Diagnostic hepatitis B infection ( clinical , serological , virological confirmation ) completion A3L12 study procedure Subjects know received hepatitis B vaccine completion A3L12 study procedure Receipt vaccine 4 week precede trial vaccination , except Bacille Calmette Guerin ( BCG ) vaccination ( administration oral polio vaccine [ OPV ] context oral polio vaccinenational immunization day [ OPVNIDs ] fall within scope exclusion criterion ) Receipt blood , bloodderived product immunosuppressant drug late 3 month inclusion Known suspect diagnostic congenital acquire immunodeficiency since completion A3L12 study procedure Serious chronic illness occur receipt primary series ( e.g. , leukemia , lymphoma [ T B cell ] , Crohn 's disease ) Known suspect subject seropositivity human immunodeficiency virus ( HIV ) hepatitis C since completion A3L12 study procedure Febrile ( temperature ≥ 38.0°C ) acute , moderate severe systemic illness day inclusion .</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Hepatitis B</keyword>
	<keyword>DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine</keyword>
	<keyword>Euvax-B®</keyword>
	<keyword>Hexaxim®</keyword>
	<keyword>Infanrix® hexa</keyword>
</DOC>